TWI256950B - Indanyl-substituted benzenecarboxamides, processes for their preparation, their use as a medicament and pharmaceutical formulations containing them - Google Patents

Indanyl-substituted benzenecarboxamides, processes for their preparation, their use as a medicament and pharmaceutical formulations containing them

Info

Publication number
TWI256950B
TWI256950B TW089112238A TW89112238A TWI256950B TW I256950 B TWI256950 B TW I256950B TW 089112238 A TW089112238 A TW 089112238A TW 89112238 A TW89112238 A TW 89112238A TW I256950 B TWI256950 B TW I256950B
Authority
TW
Taiwan
Prior art keywords
benzenecarboxamides
indanyl
medicament
substituted
processes
Prior art date
Application number
TW089112238A
Other languages
English (en)
Inventor
Joachim Brendel
Uwe Gerlach
Heinrich Steude
Hans-Jochen Lang
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of TWI256950B publication Critical patent/TWI256950B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/23Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/26Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
TW089112238A 1999-06-25 2000-06-22 Indanyl-substituted benzenecarboxamides, processes for their preparation, their use as a medicament and pharmaceutical formulations containing them TWI256950B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19929076A DE19929076A1 (de) 1999-06-25 1999-06-25 Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
TWI256950B true TWI256950B (en) 2006-06-21

Family

ID=7912468

Family Applications (1)

Application Number Title Priority Date Filing Date
TW089112238A TWI256950B (en) 1999-06-25 2000-06-22 Indanyl-substituted benzenecarboxamides, processes for their preparation, their use as a medicament and pharmaceutical formulations containing them

Country Status (31)

Country Link
US (1) US6221866B1 (zh)
EP (1) EP1194403B1 (zh)
JP (1) JP4527918B2 (zh)
KR (1) KR20020023962A (zh)
CN (1) CN1157372C (zh)
AR (1) AR024443A1 (zh)
AT (1) ATE248811T1 (zh)
AU (1) AU771601B2 (zh)
BR (1) BR0011938A (zh)
CA (1) CA2377087A1 (zh)
CZ (1) CZ20014523A3 (zh)
DE (2) DE19929076A1 (zh)
DK (1) DK1194403T3 (zh)
EE (1) EE04464B1 (zh)
ES (1) ES2200886T3 (zh)
HK (1) HK1047575B (zh)
HU (1) HUP0201711A3 (zh)
IL (1) IL147220A0 (zh)
MX (1) MXPA01012281A (zh)
NO (1) NO20015816D0 (zh)
NZ (1) NZ516347A (zh)
PL (1) PL352985A1 (zh)
PT (1) PT1194403E (zh)
RU (1) RU2238934C2 (zh)
SI (1) SI1194403T1 (zh)
SK (1) SK19092001A3 (zh)
TR (1) TR200103701T2 (zh)
TW (1) TWI256950B (zh)
WO (1) WO2001000573A1 (zh)
YU (1) YU88801A (zh)
ZA (1) ZA200109732B (zh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6970362B1 (en) 2000-07-31 2005-11-29 Intel Corporation Electronic assemblies and systems comprising interposer with embedded capacitors
US6775150B1 (en) 2000-08-30 2004-08-10 Intel Corporation Electronic assembly comprising ceramic/organic hybrid substrate with embedded capacitors and methods of manufacture
PE20020510A1 (es) 2000-09-20 2002-06-12 Upjohn Co DERIVADOS DE AZEPILO [4,5b] INDOLINA SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE SEROTONINA (5-HT)
DE10121002A1 (de) * 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
ES2378620T3 (es) 2003-03-27 2012-04-16 Cytokinetics, Inc. Sulfonamidas para el tratamiento de insuficiencia cardiaca congestiva, sus composiciones y usos.
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
US7368582B2 (en) 2003-10-17 2008-05-06 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
DE102005028845A1 (de) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
US20090247572A1 (en) * 2005-08-23 2009-10-01 Koichi Wada Agent for treating atrial fibrillation
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
CN101636154B (zh) * 2006-04-27 2011-12-14 塞诺菲-安万特德国有限公司 Task-1和task-3离子通道抑制剂
WO2008014199A2 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 receptor
KR20090069318A (ko) 2006-09-25 2009-06-30 베링거 인겔하임 인터내셔날 게엠베하 Cb2 수용체를 조절하는 화합물
WO2008098025A1 (en) * 2007-02-08 2008-08-14 Boehringer Ingelheim International Gmbh Arylsulfonamide compounds which modulate the cb2 receptor
JP4891111B2 (ja) * 2007-02-16 2012-03-07 富士フイルム株式会社 ズームレンズ
DE602008000809D1 (de) 2007-03-23 2010-04-29 Icagen Inc Ionenkanal-Hemmer
EP2217565B1 (en) * 2007-11-07 2013-05-22 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
JP5749162B2 (ja) * 2008-07-10 2015-07-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb2受容体を調節するスルホン化合物
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
KR20110063438A (ko) 2008-09-25 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 Cb2 수용체를 선택적으로 조절하는 설포닐 화합물
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (en) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
JP2013505295A (ja) * 2009-09-22 2013-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb2受容体を選択的に調節する化合物
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
WO2011109324A1 (en) 2010-03-05 2011-09-09 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the cb2 receptor
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (zh) 2011-07-01 2018-04-28
NZ627942A (en) 2012-01-27 2016-03-31 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
EP3366683A1 (en) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
JP2022530989A (ja) * 2019-05-03 2022-07-05 プラクシス プレシジョン メディシンズ, インコーポレイテッド Kcnt1阻害剤および使用する方法
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
WO2023211855A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising a thiophene core and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234944A (en) 1986-08-21 1993-08-10 Roussel Uclaf Novel indanes
DE3781627T2 (de) * 1986-08-21 1993-05-06 Roussel Uclaf Indanderivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, diese enthaltende pharmazeutische zusammensetzungen und erhaltene zwischenprodukte.
DK626889A (da) 1988-12-16 1990-06-17 Roussel Uclaf Indanderivater, deres fremstilling samt laegemidler med indhold deraf
US5348971A (en) 1988-12-16 1994-09-20 Roussel Uclaf Indanes useful as analgesics
FR2708608B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
CA2180841C (en) * 1994-01-10 2007-03-27 Sasson Cohen 1-aminoindan derivatives and compositions thereof
US6083986A (en) * 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
DE19707656A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Sulfonamid-substituierte anellierte 7-Ring-Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
BR9811845A (pt) * 1997-08-05 2000-08-08 American Home Prod Análogos do ácido antranìlico
DE19749453A1 (de) * 1997-11-10 1999-05-12 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte anellierte 5-Ring-Verbindungen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
SI1194403T1 (en) 2003-12-31
EE200100684A (et) 2003-04-15
NO20015816L (no) 2001-11-29
HUP0201711A3 (en) 2005-05-30
HK1047575A1 (en) 2003-02-28
DE19929076A1 (de) 2000-12-28
DE50003555D1 (de) 2003-10-09
PT1194403E (pt) 2004-01-30
JP4527918B2 (ja) 2010-08-18
HUP0201711A2 (en) 2002-09-28
CN1157372C (zh) 2004-07-14
AR024443A1 (es) 2002-10-02
CZ20014523A3 (cs) 2002-04-17
RU2238934C2 (ru) 2004-10-27
EP1194403A1 (de) 2002-04-10
DK1194403T3 (da) 2003-12-08
AU5531800A (en) 2001-01-31
NZ516347A (en) 2004-01-30
IL147220A0 (en) 2002-08-14
YU88801A (sh) 2004-09-03
CN1358172A (zh) 2002-07-10
EP1194403B1 (de) 2003-09-03
ZA200109732B (en) 2002-08-30
HK1047575B (zh) 2004-12-31
KR20020023962A (ko) 2002-03-29
US6221866B1 (en) 2001-04-24
WO2001000573A1 (de) 2001-01-04
JP2003503385A (ja) 2003-01-28
CA2377087A1 (en) 2001-01-04
MXPA01012281A (es) 2002-07-30
SK19092001A3 (sk) 2002-06-04
EE04464B1 (et) 2005-04-15
NO20015816D0 (no) 2001-11-29
ATE248811T1 (de) 2003-09-15
ES2200886T3 (es) 2004-03-16
TR200103701T2 (tr) 2002-05-21
BR0011938A (pt) 2002-03-19
AU771601B2 (en) 2004-03-25
PL352985A1 (en) 2003-09-22

Similar Documents

Publication Publication Date Title
TWI256950B (en) Indanyl-substituted benzenecarboxamides, processes for their preparation, their use as a medicament and pharmaceutical formulations containing them
MY143521A (en) Anthranilamides and methods of their use
MY138341A (en) Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use
HK1066539A1 (en) Ortho-substituted nitrogen-containing bisaryl compounds use as potassium channel inhibitors
YU24402A (sh) 2'-supstituisani 1,1'-bifenil-2-karbonamidi, postupak za njihovu proizvodnju, njihova primena kao leka kao i farmaceutski preparati koji sadrže ta jedinjenja
YU42503A (sh) Arilovani furan-1 tiofen-amidi-karbonske kiseline sa blokirajućim dejstvom kalijumovog kanala
AR031430A1 (es) Compuestos de bisarilo orto, meta-sustituidos, procedimientos para su preparacion, su utilizacion como medicamento como tambien los preparados farmaceuticos que los contienen
CA2396561A1 (en) Substituted oxazolidinones and their use in the field of blood coagulation
CA2326756A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
NO20003233L (no) 4-hydroksykinolin-3-karboksamider og hydrazider som antivirale midler
CA2178760A1 (en) HIV Protease Inhibitors
AU2108500A (en) Galenic formulation containing biotin
HK1120794A1 (en) Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
AU1727797A (en) Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
BR0016678A (pt) Composto, formulação farmacêutica, uso de um composto, método para profilaxia ou tratamento de uma arritmia, e, processo para preparação de um composto
MX9603300A (es) Derivados de la 4-sulfonilbenzoilguanidina o la 4-sulfinilbenzoilguanidina.
SE0003795D0 (sv) Pharmaceutically useful compounds
MXPA05009763A (es) 2-(butil-1-sulfonilamino)-n-[1 (r)-(6-metoxipiridin-3-il) propil] benzamida, su uso en forma de un farmaco y preparaciones farmaceuticas que contienen a dicho compuesto.
WO2000002877A3 (en) New pharmaceutically active compounds
AU4302996A (en) Uracil derivatives
SE9902269D0 (sv) Pharmaceutically active compounds

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees